Sec Form 4 Filing - Versant Ventures V, LLC @ Repare Therapeutics Inc. - 2021-06-01

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Versant Ventures V, LLC 2. Issuer Name and Ticker or Trading Symbol Repare Therapeutics Inc. [ RPTX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) ONE SANSOME STREET, SUITE 3630 3. Date of Earliest Transaction (MM/DD/YY) 06/01/2021 (Street) SAN FRANCISCO, CA94104 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Shares 06/01/2021 J( 1 ) 75,000 D $ 0 383,282 I See Footnote ( 2 ) Common Shares 06/01/2021 J( 3 ) 1,128 A $ 0 1,128 I See Footnote ( 4 ) Common Shares 06/01/2021 J( 5 ) 1,128 D $ 0 0 I See Footnote ( 4 ) Common Shares 06/01/2021 J( 6 ) 1,119 A $ 0 1,119 I See Footnote ( 7 ) Common Shares 06/01/2021 J( 8 ) 1,119 D $ 0 0 I See Footnote ( 7 ) Common Shares 2,594,451 I See Footnote ( 9 ) Common Shares 1,903,670 I See Footnote ( 10 ) Common Shares 57,264 I See Footnote ( 11 ) Common Shares 63,387 I See Footnote ( 12 ) Common Shares 144,879 I See Footnote ( 13 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Versant Ventures V, LLC ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA94104 X Versant Ophthalmic Affiliates I, L.P. ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA94104 X Versant Affiliates Fund V, L.P. ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA94104 X Versant Venture Capital V (Canada), LP ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA94104 X Versant Ventures V GP-GP (Canada), Inc. ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA94104 X Versant Venture Capital V, L.P. ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA94104 X Versant Venture Capital VI, L.P. ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA94104 X Versant Ventures VI GP, L.P. ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA94104 X Versant Ventures VI GP-GP, LLC ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA94104 X Versant Ventures V (Canada), L.P. ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA94104 X Signatures /s/ Robin L. Praeger, Managing Director of Versant Ventures V, LLC 06/03/2021 Signature of Reporting Person Date /s/ Robin L. Praeger, Managing Director of Versant Ventures V, LLC, general partner of Versant Ophthalmic Affiliates Fund I, L.P. 06/03/2021 Signature of Reporting Person Date /s/ Robin L. Praeger, Managing Director of Versant Ventures V, LLC, general partner of Versant Affiliates Fund V, L.P. 06/03/2021 Signature of Reporting Person Date /s/ Robin L. Praeger, Director of Versant Ventures V GP-GP (Canada), Inc., general partner of Versant Ventures V (Canada), L.P., the general partner of Versant Venture Capital V (Canada) LP 06/03/2021 Signature of Reporting Person Date /s/ Robin L. Praeger, Director of Versant Ventures V GP-GP (Canada), Inc., general partner of Versant Ventures V (Canada), L.P. 06/03/2021 Signature of Reporting Person Date /s/ Robin L. Praeger, Director of Versant Ventures V GP-GP (Canada), Inc. 06/03/2021 Signature of Reporting Person Date /s/ Robin L. Praeger, Managing Director of Versant Ventures VI GP-GP LLC, general partner of Versant Ventures VI GP, L.P., the general partner of Versant Venture Capital VI, L.P. 06/03/2021 Signature of Reporting Person Date /s/ Robin L. Praeger, Managing Director of Versant Ventures VI GP-GP LLC, general partner of Versant Ventures VI GP, L.P. 06/03/2021 Signature of Reporting Person Date /s/ Robin L. Praeger, Managing Director of Versant Ventures VI GP-GP LLC 06/03/2021 Signature of Reporting Person Date /s/ Robin L. Praeger, Managing Director of Versant Ventures V, LLC, the general partner of Versant Venture Capital V, L.P. 06/03/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I, L.P. ("VV I"), to its partners. ( 2 )Shares held by VV I. Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. ( 3 )Represents a change in the form of ownership of VV I GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV I. ( 4 )Shares held by VV I GP. VV I GP-GP is the sole general partner of VV I GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP. Each of VV I GP-GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV I GP, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. ( 5 )Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP, to its partners. ( 6 )Represents a change in the form of ownership of VV I GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV I GP. ( 7 )Shares held by VV I GP-GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. ( 8 )Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP-GP, to its members. ( 9 )Shares held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. Each of VV VI GP, VV VI and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. ( 10 )Shares held by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. ( 11 )Shares held by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. ( 12 )Shares held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I"). VV V is the sole general partner of VOAF I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. ( 13 )Shares held by Versant Venture Capital V (Canada) LP ("VVC V (Canada)"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.

Remarks: 1 of 2: Since there are 13 joint filers with this transaction and EDGAR will not allow for entry of more than 10 joint filers, this Form 4 is being filed in conjunction with a Form 4 for Versant Vantage I, LP, Versant Vantage I GP, L.P. and Versant Vantage I GP-GP, LLC.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.